Literature DB >> 27222061

Tanshinone IIA Protects Against Folic Acid-Induced Acute Kidney Injury.

Chunming Jiang1, Wei Zhu1, Qiuyuan Shao1, Xiang Yan2, Bo Jin1, Miao Zhang1, Biao Xu3.   

Abstract

Tanshinone IIA is a diterpene extracted from Salvia miltiorrhiza, a popular and safe herb medicine that has been widely used in China and other Asian countries. Previous studies have demonstrated the pleiotropic effects of Tanshinone IIA on many disease treatments via its antitoxicity, anti-inflammation, anti-oxidative stress, as well as antifibrosis activities. However, its effect on acute kidney injury (AKI) has not been fully investigated. Here, we show for the first time that systemic administration of Tanshinone IIA can lead to improved kidney function in folic acid-induced kidney injury mice. In the acute phase of AKI, Tanshinone IIA attenuated renal tubular epithelial injury, as determined by histologic changes and the detection of Neutrophil gelatinase-associated lipocalin (NGAL) in the kidney and urine. Additionally, Tanshinone IIA treatment resulted in elevated proliferating cell nuclear antigen (PCNA) expression and decreased inflammatory cells infiltration as well as chemokine expression, suggesting that Tanshinone IIA promoted renal repair following AKI and inhibited local inflammatory response in the injured kidney. This led to decreased long-term fibrosis in the injured kidney, characterized by less accumulation of fibronectin and collagen I in tubulointerstitium. Taken together, these results suggest that Tanshinone IIA may represent a potential approach for AKI treatment.

Entities:  

Keywords:  Acute Kidney Injury; Apoptosis; Fibrosis; Inflammation; Tanshinone IIA

Mesh:

Substances:

Year:  2016        PMID: 27222061     DOI: 10.1142/S0192415X16500403

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  8 in total

1.  DNA Methylome and Transcriptome Alterations in High Glucose-Induced Diabetic Nephropathy Cellular Model and Identification of Novel Targets for Treatment by Tanshinone IIA.

Authors:  Wenji Li; Davit Sargsyan; Renyi Wu; Shanyi Li; Lujing Wang; David Cheng; Ah-Ng Kong
Journal:  Chem Res Toxicol       Date:  2019-09-17       Impact factor: 3.739

2.  Roxadustat (FG-4592) Facilitates Recovery From Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid.

Authors:  Xue Li; Bo Jiang; Yu Zou; Jie Zhang; Yuan-Yuan Fu; Xiao-Yue Zhai
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

3.  Tanshinone IIA prevents left ventricular remodelling via the TLR4/MyD88/NF-κB signalling pathway in rats with myocardial infarction.

Authors:  Dong-Mei Wu; Yong-Jian Wang; Xin-Rui Han; Xin Wen; Lei Li; Lan Xu; Jun Lu; Yuan-Lin Zheng
Journal:  J Cell Mol Med       Date:  2018-03-10       Impact factor: 5.310

Review 4.  Mechanisms and Efficacy of Chinese Herbal Medicines in Chronic Kidney Disease.

Authors:  Mingming Zhao; Yi Yu; Rumeng Wang; Meiying Chang; Sijia Ma; Hua Qu; Yu Zhang
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

5.  Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy.

Authors:  Wei Lv; Mei-Rong Wang; Cheng-Zhen Zhang; Xue-Xu Sun; Zhen-Zhen Yan; Xiao-Min Hu; Tao-Tao Wang
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

Review 6.  Folic acid-induced animal model of kidney disease.

Authors:  Liang-Jun Yan
Journal:  Animal Model Exp Med       Date:  2021-11-24

Review 7.  Promoting Plant-Based Therapies for Chronic Kidney Disease.

Authors:  Muhammad Ali Khan; Andrew J Kassianos; Wendy E Hoy; Ahm Khurshid Alam; Helen G Healy; Glenda C Gobe
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

Review 8.  Application of Herbal Traditional Chinese Medicine in the Treatment of Acute Kidney Injury.

Authors:  Hai-Di Li; Xiao-Ming Meng; Cheng Huang; Lei Zhang; Xiong-Wen Lv; Jun Li
Journal:  Front Pharmacol       Date:  2019-04-18       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.